MetaVia (MTVA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
The annual meeting will be held virtually on June 8, 2026, with voting on five key proposals, including director elections, auditor ratification, a reverse stock split, an equity plan amendment, and potential adjournment.
The Board unanimously recommends voting in favor of all proposals.
Only stockholders of record as of April 13, 2026, are entitled to vote, with each share representing one vote.
Forward-looking statements are included, subject to risks and uncertainties as detailed in the company's filings.
Voting matters and shareholder proposals
Proposal 1: Election of two Class I directors for three-year terms.
Proposal 2: Ratification of BDO USA, P.C. as independent auditor for 2026.
Proposal 3: Approval of a reverse stock split at a ratio between 1-for-5 and 1-for-22, at Board discretion.
Proposal 4: Amendment to the 2022 Equity Incentive Plan to add 200,000 shares.
Proposal 5: Authorization to adjourn the meeting if more votes are needed for Proposals 3 and 4.
Board of directors and corporate governance
The Board consists of seven members, with staggered three-year terms.
Six directors are independent under Nasdaq and SEC rules; the CEO is not independent.
Committees include audit, compensation, and nominating/corporate governance, each with defined charters and responsibilities.
Corporate governance guidelines, code of conduct, and insider trading policy are in place and available online.
Board and committee meetings are held regularly, with high attendance.
Latest events from MetaVia
- Annual meeting to vote on directors, auditor, reverse split, and equity plan amendment.MTVA
Proxy filing27 Apr 2026 - Promising obesity and MASH therapies advance with strong early data and major market potential.MTVA
Investor presentation26 Mar 2026 - Strong clinical progress and improved financials position the pipeline for key 2026 milestones.MTVA
Q4 202526 Mar 2026 - DA-1726 and vanoglipel advance in clinical trials, with key data and partnerships expected this year.MTVA
Emerging Growth Virtual Conference25 Feb 2026 - Biotech seeks $6M via unit offering to fund clinical programs, with significant dilution risk.MTVA
Registration Filing12 Jan 2026 - Biotech seeks $12.8M via unit offering to fund MASH/obesity drug trials amid ongoing losses.MTVA
Registration Filing5 Jan 2026 - 14M shares registered for resale after private placement; biotech faces ongoing losses and key risks.MTVA
Registration Filing16 Dec 2025 - Key votes include director elections, a reverse stock split, and share issuance approval tied to Dong-A.MTVA
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, reverse split, and major share issuance.MTVA
Proxy Filing2 Dec 2025